Tag: CX 2024
Venous News 18 – June 2024
In this issue:
In Profile: Gloria Salazar (Chapel Hill, USA)
Gerry O'Sullivan (Galway, Ireland), Steve Black (London, UK), and Erin Murphy (Charlotte, USA) discuss stenting...
Venous News 18 – June 2024: US Edition
In this issue:
In Profile: Gloria Salazar (Chapel Hill, USA)
Gerry O'Sullivan (Galway, Ireland), Steve Black (London, UK), and Erin Murphy (Charlotte, USA) discuss stenting...
CX panel confronts conundrum of the moment: Should NIVL patients get...
Should non-thrombotic iliac vein lesion (NIVL) patients be given venous stents? That was the question raised to Gerry O’Sullivan (Galway, Ireland), a consultant interventional...
New randomized controlled data from VenaSeal Spectrum Program reinforces evidence that...
“The initial results of two of the three studies in the VenaSeal Spectrum Program reinforce the safety and effectiveness of the VenaSeal system as...
CX 2024 venous programme has “a lot to look forward to,”...
Erin Murphy (Atrium Health’s Sanger Heart and Vascular Institute, Charlotte, USA), one of the CX Symposium cochairs and a CX Executive Board member, along...
Why treat DVT interventionally with a “wall-to-wall” mechanical thrombectomy approach?
In a recent interview, Marie Josee van Rijn from Rotterdam, the Netherlands and Emma Wilton from Oxford, UK, provided insight into the transformative power...
CX 2024 programme seeks to challenge venous controversy ‘head on’ to...
Forecasting their Charing Cross (CX) 2024 venous programme highlights, executive board members Manj Gohel (London, United Kingdom), Erin Murphy (Charlotte, USA) and Stephen Black...